Search
Opium
go.drugbank.com/drugs/DB11130ApprovedIllicitin the category of isoquinolines. … There is some legal production of opium in different countries for the obtention of alkaloids by extraction.[L1766]
Gatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnpatients taking gatifloxacin compared to those on macrolide antibiotics. … It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections.
Categories: Compounds used in a research, industrial, or household settingCilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCompared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium … This drug is approved in China, Japan, Korea, India, and several countries in the European Union.[A31970]
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … CGRP receptors are expressed in the central and peripheral nervous system; however, CGRP does not cross the blood-brain barrier, suggesting that it acts on peripheral nerves.
Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … [A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823]
Donanemab
go.drugbank.com/drugs/DB16647ApprovedInvestigational[A232214] On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms. … Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Pancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigational[L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Synonyms: 4'-N-benzoylstaurosporine